Active Filter(s):
Details:
Through the license agreement, MC2 will gain the commercialization rights for Wynzora consisting of Calcipotriene and Betamethasone dipropionate. It is an approved product indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Product Name: Wynzora
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hyphens Pharma
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 12, 2024
Details:
The product is the combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. It is indicated for the topical treatment of plaque psoriasis.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Product Name: Enstilar-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in aqueous formulation.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Product Name: Wynzora
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: MC2 Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Product Name: Wynzora
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Almirall
Deal Size: Undisclosed Upfront Cash: $18.0 million
Deal Type: Collaboration February 17, 2021
Details:
U.S. Prescribing Information (USPI) updated to include PSO-LONG clinical trial data concerning long-term use (52 weeks) of twice-weekly topical treatment with Enstilar® (calcipotriene and betamethasone dipropionate) Foam in adults with plaque psoriasis.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Product Name: Enstilar
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA® Cream to patients with plaque psoriasis in the US. WYNZORA® Cream is the first drug based on PADTM Technology – providing innovative solutions to unmet needs in chronic inflammatory conditions.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Product Name: Wynzora
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: MC2 Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2020